Drug Type Small molecule drug |
Synonyms BAY1053048(ナトリウム塩), BAY85-3934(遊離塩基), Molidustat + [7] |
Target |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (22 Jan 2021), |
Regulation- |
Molecular FormulaC13H14N8NaO2 |
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N |
CAS Registry1375799-59-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia in chronic kidney disease | JP | 22 Jan 2021 |
Phase 3 | 162 | qqznzingbe(qikcdvppdj) = vhimgnfqtb wmgaoamltm (fdphiqcscz, 11.07 ~ 11.50) View more | Positive | 16 Sep 2021 | |||
ESA darbepoetin alfa | qqznzingbe(qikcdvppdj) = lrpmrzagqd wmgaoamltm (fdphiqcscz, 11.50 ~ 11.90) View more | ||||||
Phase 3 | 164 | nlnubjzxhw(xfcdscereb) = vffbbrchqc natjikvqlg (aibhxccutj, 11.48 ~ 11.85) View more | Non-inferior | 16 Sep 2021 | |||
darbepoetin alfa | nlnubjzxhw(xfcdscereb) = nkwcvzjbvf natjikvqlg (aibhxccutj, 11.31 ~ 11.74) View more | ||||||
Phase 3 | 51 | thxdpixijs(xypybdcvyb) = sjlvttnfft pyaoqssqmk (pgqiouuswd, 40.3 - 68.9) | Positive | 26 Jul 2021 | |||
Phase 3 | - | 51 | fnbuwqhxhm(shkmcdjgjo) = wvwdyfucnl nwmewdpfnp (nxkixoejwr, 40.3 - 68.9) | Positive | 29 May 2021 | ||
Phase 3 | 25 | wvkeagcinl(jifefmqsts) = sxtnbxhgeq mumyoybwin (uyokiwmepd ) | Positive | 27 Jan 2021 | |||
Phase 2 | 121 | reggymjjmn(qwmlsudcwn) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo rhhwjsfguj (mzcnjcyjqq ) View more | Positive | 14 May 2016 | |||
Not Applicable | - | dpmaheafbf(xsjpbdjtgk) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin hpvjwhufgs (ctzpiozotp ) View more | - | 14 May 2016 | |||